Fabrication of A Folic Acid-Modified Arsenic Trioxide Prodrug Liposome and Assessment of its Anti-Hepatocellular Carcinoma Activity

Fabrication of A Folic Acid-Modified Arsenic Trioxide Prodrug Liposome and Assessment of its Anti-Hepatocellular Carcinoma Activity

Objective: To reduce the toxicity and side effects of arsenic trioxide (ATO) and provide a new approach for the treatment of primary liver cancer, a folic acid-modified calcium arsenite liposomal “target-controlled” drug delivery system (FA-LP-CaAs) was fabricated using the reverse microemulsion met...

Full description

Bibliographic Details
Main Authors: Zhu Jing-Jing, Chen Xiao-Jie, Yao Wen-Dong, Wei Ying-Hui, Zheng Hang-Sheng, Zheng Hong-Yue, Zhu Zhi-Hong, Wang Bin-Hui, Li Fan-Zhu
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2020-12-01
Series:Digital Chinese Medicine
Subjects:
Target-controlled drug delivery system
Liver cancer
Arsenic trioxide
Calcium arsenite
Liposomes
pH-sensitive
Online Access:http://www.sciencedirect.com/science/article/pii/S2589377720300690

Internet

http://www.sciencedirect.com/science/article/pii/S2589377720300690

Similar Items